Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir

Children with high-risk SHH/TP53-mut and Group 3 medulloblastoma (MB) have a 5-year overall survival of only 40%. Innovative approaches to enhance survival while preventing adverse effects are urgently needed. We investigated an innovative therapy approach combining irradiation (RT), decitabine (DEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gringmuth, Marieke, Walther, Jenny, Greiser, Sebastian, Toussaint, Magali, Schwalm, Benjamin, Kool, Marcel, Kortmann, Rolf-Dieter, Glasow, Annegret, Patties, Ina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998934/
https://www.ncbi.nlm.nih.gov/pubmed/35409174
http://dx.doi.org/10.3390/ijms23073815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998934/
https://www.ncbi.nlm.nih.gov/pubmed/35409174
http://dx.doi.org/10.3390/ijms23073815

Ejemplares similares